Source: https://www.lawyersandjudges.com/products/odonnells-drug-injury-fourth-edition
Timestamp: 2019-04-24 16:04:19+00:00

Document:
O'Donnell's Drug Injury, Fourth Edition – Lawyers & Judges Publishing Company, Inc.
If you are involved with the healthcare system as a practitioner or attorney, you know that cases involving drug-induced injury are as complex as they are common. While the injury to the patient might seem obvious, in reality that has very little effect on the course that the litigation will take. This makes it especially important to accurately evaluate the case.
Whether prosecuting or defending, you will want to be sure that the case has merit or can be successfully defended. To accomplish this, you need the knowledge of the drug development, regulation, pharmacists practice, and which drugs cause the most injuries. This is all carefully detailed in this new fourth edition by a medley of well-accomplished authors.
Easy for the non-medical professional to follow, the book is divided into four useful sections. Part I deals with the pharmaceutical process, covering the liability of pharmaceutical companies, warning labels and clinical trials. Part II examines high-risk drug therapies that result in pharmaceutical litigation. You’ll read about important litigation regarding drugs like opiates and pain medications, anticoagulants, steroids, insulin and oral diabetic drugs, as well as allergic reactions, and liver/kidney injuries caused by drugs. Whether or not your case involves the drug cited you’ll find that the theories applicable to one pharmaceutical case are often applicable to another. Part III looks at the professional pharmacist and malpractice claims. Finally, Part IV covers forensic and toxicological issues, particularly recreational drugs, drug testing, and pain equipotency.
You’ll find this text indispensable for the comprehensive information it provides for all those affiliated with the use of drugs in healthcare, in the community, and in the pharmaceutical industry.
Marijuana-Impaired or Just Cannabinoid Positive?
See Errata for page 88 here.
Mary E. Kremzner, Pharm.D., MPH, CAPT, USPHS and Justina A. Molzon, M.S. Pharm., J.D.
1.23 Classification as Food or Drug?
Justina A. Molzon, M.S. Pharm., J.D. and James T. O’Donnell, Pharm.D., M.S., FCP, ABCP, FACN, R.Ph.
Stephen Barrett, M.D. and Robert S. Baratz, M.D., DDS, Ph.D.
A. Why Do We Need Research Oversight?
Frank J. Ascione, Pharm.D., MPH, Ph.D. and Nithima Sumpradit, B.S.Pharm., M.A., Ph.D.
Compiled by S. Albert Edwards, Pharm.D., RAC, FRAPS.
9.8 Legislative Measures in the U.S.
James J. O’Donnell III, M.S., Ph.D., James T. O’Donnell, Pharm.D., M.S., FCP, ABCP, FACN, R.Ph., and Vanessa Juettner, M.S.
Joseph J. Bogdan, Pharm.D., R.Ph., J.D.
James T. O’Donnell, Pharm.D., M.S., FCP, ABCP, FACN, R.Ph. and James J. O’Donnell III, M.S., Ph.D.
14.1 Adverse Drug Reactions (ADRs): How Large is the Problem? What Drugs are Involved? What are the Injuries?
Donald H. Marks, M.D., Ph.D.
15.9 Does Causation Need to be Established Before a Warning is Given?
15.10 What are the Qualifications Needed to Give Causation Opinions?
17.8 How Has Modern Research Improved Therapeutics and Reduced Drug-Related Morbidity?
1. Woulfe v. Eli Lilly & Co.
2. Espinoza v. Eli Lilly & Co.
3. Cassidy v. Eli Lilly & Co.
1. Schilf v. Eli Lilly & Co.
B. Stebbins v. Concord Wrigley Drugs, Inc. et al.
C. Morgan et al. v. Wal-Mart Stores, Inc.
20.16 How Safe is it to Buy Prescription Medications Over the Internet?
Domenic A. Sica, M.D. and Todd W. B. Gehr, M.D.
A. What Constitutes Prompt Clinical Action in the Face of Nephrotoxicity?
James T. O’Donnell, Pharm.D., M.S., FCP, ABCP, FACN, R.Ph., Donald H. Marks, M.D., Ph.D., Paul N. Danese, Ph.D., and James J. O’Donnell III, M.S., Ph.D.
James T. O’Donnell, Pharm.D., M.S., FCP, ABCP, FACN, R.Ph.
Jadwiga Najib, B.S.,Pharm.D. and Meagan Bailey, M.D.
James J. O’Donnell III, M.S., Ph.D. and James T. O’Donnell, Pharm.D., M.S., FCP, ABCP, FACN, R.Ph.
D. Dissemination of Evidence in Reducing Injuries from Falls: Awareness and Intervention Works!
31.4 What Are the Benefits of Using Ketorolac?
31.5 What Are the Risks of Using Ketorolac?
D. Quotas and Metrics: Contributing to the Problem?
Roger N. Morris, R.Ph., J.D. and William J. Stilling, R.Ph., M.S., J.D.
Loyd V. Allen, Jr., B.S., M.S., Ph.D.
Peter D. Anderson, Pharm.D., BCPP, CMI-IV and James T. O’Donnell, Pharm.D., M.S., FCP, ABCP, FACN, R.Ph.
James J. O’Donnell III, M.S., Ph.D., James T. O’Donnell, Pharm.D., M.S., FCP, ABCP, FACN, R.Ph., and Anne D. ImObersteg, M.S., J.D., MBA, B.A.
Chapter 50: Marijuana-Impaired or Just Cannabinoid Positive?
John P. Bederka, Jr., Ph.D.
1. Blood THC v. brain THC: any relationships?
5. Is THC the only psycho-active cannabinoid?
6. Urine testing for cannabinoids: clinical or evidentiary value?
1. How do bioavailability measures relate to ingestion?
2. Is Dronabinol administration a good model for cannabis Ingestion?
3. Any overall advantages of the oromucosal route?
4. Can the effects after ingestion of cannabis be made more objective?

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 V. 
 v.